Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common...
MannKind Announces CFO Transition
INHALE-3 Study™s Initial Meal Challenge Results Comparing Afrezza®
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented
MannKind Corporation Announces Participation at Upcoming Conferences
2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 fourth quarter and full year financial results and its...
MANNKIND ANNOUNCES ENROLLMENT GOAL COMPLETION OF INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING AFREZZA
Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net salesPurchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif., Jan. 02, 2024 ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of inhaled therapeutic...